Actinium Pharmaceuticals CD33 Program to Focus on Actimab-MDS Pivotal Trial Enabling Study for Targeted Conditioning and Novel Combination Trials with Actimab-A and Venetoclax Oct 30, 2018
Actinium Pharmaceuticals to Hold Webinar Showcasing Actimab-A Post Phase 2 Trial Plans and Actimab-MDS Regulatory Update Oct 26, 2018
Actinium Pharmaceuticals Announces Participation at BIO-Europe® 24th Annual International Partnering Conference Oct 24, 2018
Actinium Pharmaceuticals Announces Webinar Showcasing Actimab-A Post Phase 2 Trial Plans and Actimab-MDS Regulatory Update Oct 22, 2018
Actinium Launches Iomab-ACT Program Offering Its Targeted, Chemo-Free, Lymphodepletion Technology as a Universal Solution to CAR-T Product Developers Oct 1, 2018
Actinium Pharmaceuticals to Host Webinar Today Introducing Next Generation Targeted Lymphodepletion Technology for CAR-T Sep 26, 2018
Actinium Pharmaceuticals to Participate in the Oppenheimer & Co. Fall Summit Focused on Specialty Pharma and Rare Disease Sep 20, 2018
Actinium Pharmaceuticals to Host Webinar Showcasing New Pipeline Initiative Focused on the CAR-T Space Sep 18, 2018
Actinium Appoints Robert N. Daly, Ph.D. to Newly Created Role of Vice President, Head of Clinical Operations Sep 6, 2018
Actinium Pharmaceuticals to Present at Upcoming Investor Conferences and Participate in Featured Panel Discussions Sep 4, 2018
